Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug Policy, Pricing & Approval stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 15, 2026

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00
Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 6, 2026

FDA launches investigation into Novartis' Zolgensma over cancer cases

The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.

Nov 6, 2026·2 sources
00

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources
00

Revolution Medicines' pancreatic cancer drug Rasonque posts record launch

Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.

Nov 5, 2026·3 sources
00
Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Nov 2, 2026

Cerus blood-safety system meets primary endpoint in late-stage trial

Cerus Corp announced that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients requiring transfusions in a late-stage study.

Nov 2, 2026·2 sources
00

FDA approves generic version of HIV-prevention shot lenacapavir

The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV, a significant step toward making the drug available inexpensively and more quickly in low-income countries.

Nov 2, 2026·2 sources
00

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00

Novartis heart drug failure raises questions about genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.

Nov 2, 2026·2 sources
00
Oct 30, 2026

First patient receives Sumitomo Pharma stem cell transplant for Parkinson's disease

A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.

Oct 30, 2026·3 sources
00

FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis

The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.

Oct 30, 2026·4 sources
00

FDA approves tildrakizumab for psoriatic arthritis

The FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.

Oct 30, 2026·3 sources
00

EMA reviews Lundbeck's Deanxit after reports of serious neurological side effects

The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.

Oct 30, 2026·2 sources
00

FDA removes black box warning from three estradiol transdermal patches for menopause

The U.S. Food and Drug Administration approved the removal of black box warnings from three estradiol transdermal patches used to treat menopause symptoms. The strictest FDA warnings had previously cautioned about risks of cardiovascular disease, breast cancer, and dementia.

Oct 30, 2026·3 sources
00

FDA advisory committee reviews SYD-101 atropine eye drops for pediatric myopia

An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.

Oct 30, 2026·1 source
00
Oct 28, 2026

FDA releases guidance for individualized gene editing therapies

The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.

Oct 28, 2026·2 sources
00

Labor Department finalizes rule requiring PBMs to disclose fees and compensation

The Trump administration finalized a sweeping regulation requiring pharmacy benefit managers to share detailed fee and compensation data with self-funded employer clients starting in 2027. Employers praised the transparency measure while PBMs criticized it as burdensome.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00
Oct 23, 2026

US estrogen shortage expands beyond patches to injectable and vaginal products

Women in the US seeking hormone replacement therapy for menopause symptoms are facing widening shortages that now extend beyond estrogen patches to include injectable and vaginal estrogen products, driven by surging demand.

Oct 23, 2026·3 sources
00

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

UK approves Johnson & Johnson's oral psoriasis pill for moderate-to-severe plaque psoriasis

Britain's medicines regulator approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy patches.

Oct 23, 2026·2 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

FDA approves dolutegravir HIV drug for newborns based on international clinical trial

The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.

Oct 22, 2026·3 sources
00

Quest Diagnostics reports cyberattack affecting patient records

Quest Diagnostics disclosed unauthorized access to its Quanum Lab Services Manager system, which is used by healthcare professionals to order tests and view lab results, potentially exposing patient records.

Oct 22, 2026·4 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00

Dana-Farber and Beth Israel begin construction of $1.68 billion cancer hospital

Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting construction on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Mass General Brigham AI tool predicts cancer survival from facial photographs

Researchers at Mass General Brigham have developed an AI system called FAHR-Face that can predict cancer patients' survival chances using a single photograph of their face. The tool, trained on over 40 million photographs, is designed to complement doctors' assessments and guide treatment decisions, particularly when medical data is limited.

Oct 19, 2026·14 sources
00

Carotid artery stenting fails to improve cognition in CREST-H clinical trial

A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.

Oct 19, 2026·1 source
00

Peter Mac scientists develop CRISPR method to target gene fusions in one in five cancers

Scientists at Peter MacCallum Cancer Centre have developed a new CRISPR approach using PspCas13b nuclease to precisely target abnormal gene fusions, which occur in approximately 20% of cancers. The technique targets the unique molecular fingerprint created when two genes fuse together, potentially offering a new personalized treatment strategy.

Oct 19, 2026·1 source
00
Oct 16, 2026

Texas mother's severe pregnancy heartburn misdiagnosed, later revealed as stage 3 colon cancer

Geraldine Levano, 31, of Houston experienced severe acid reflux during her second pregnancy that doctors dismissed as pregnancy-related. The unbearable symptoms were later diagnosed as stage 3 colon cancer, highlighting the dangers of dismissing persistent or severe symptoms during pregnancy.

Oct 16, 2026·2 sources
00
Oct 15, 2026

FDA advances plan allowing pharmacies to compound peptide drugs

The FDA is moving forward with a policy change that would temporarily allow specialty pharmacies to produce certain peptides, a class of largely unregulated injections favored by HHS Secretary Robert F. Kennedy Jr.

Oct 15, 2026·3 sources
00

Dexcom G7 study shows continuous glucose monitoring benefits type 2 diabetes patients not on insulin

A landmark study published in The New England Journal of Medicine found that continuous glucose monitoring devices benefit all type 2 diabetes patients, including those not taking insulin, with users achieving lower HbA1c levels and spending approximately 5 more hours per day in target glucose range. The Dexcom CONNECT study marks the first standalone real-time CGM clinical data published in NEJM in nearly two decades.

Oct 15, 2026·4 sources
00
Oct 14, 2026

Vanda Pharmaceuticals halts social anxiety drug program after Phase 3 failure

Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.

Oct 14, 2026·2 sources
00

Trump administration removes 189,000 from ACA subsidies over duplicate coverage

The Trump administration cut off Affordable Care Act subsidies for about 189,000 people identified as having duplicate government coverage or being deceased. Individual health insurance enrollment fell 18% to 20.5 million members in June, marking the steepest annual decline.

Oct 14, 2026·2 sources
00

FDA launches comprehensive review of rare disease drug approval process

The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.

Oct 14, 2026·5 sources
00

Arrowhead Pharmaceuticals' ARO-MAPT shows first evidence of tau protein reduction in Alzheimer's trial

Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.

Oct 14, 2026·4 sources
00
Oct 13, 2026

Walmart to offer over 250 free medications including GLP-1s and insulin to employees

Walmart announced it will provide more than 250 medications at no cost to its employees, including GLP-1 drugs, insulin, and inhalers, as part of an expansion of healthcare benefits for its workforce. The new benefit program represents a significant enhancement to employee healthcare coverage at the nation's largest private employer.

Oct 13, 2026·4 sources
00

UnitedHealth raises 2026 profit outlook as medical cost pressures ease

UnitedHealth Group raised its 2026 profit forecast and reported better-than-expected third-quarter earnings, signaling progress in managing elevated medical costs and its broader turnaround efforts.

Oct 13, 2026·4 sources
00
Oct 10, 2026

Trump administration announces $90 Medicare rebate for 20 million enrollees

President Trump's administration will make one-time payments of $90 per person to help more than 20 million Medicare enrollees pay for their Part B premiums, costing approximately $2 billion. Critics have characterized the move as a political stunt.

Oct 10, 2026·2 sources
00
Oct 9, 2026

Hospitals sue Trump administration over 340B drug discount rebate pilot

The American Hospital Association has filed another lawsuit against the Trump administration over plans to convert the 340B federal drug discount program from upfront discounts to after-the-fact rebates.

Oct 9, 2026·2 sources
00

Prediction markets enter pharmaceutical drug trials, raising integrity concerns

Prediction marketplaces are expanding into the pharmaceutical field, allowing users to buy and sell shares on clinical trial outcomes. Experts warn this development may threaten the integrity of drug trials as the platforms take their first steps into this new territory.

Oct 9, 2026·4 sources
00

HHS recommends science-based thresholds to target dangerous enhanced kratom products

HHS provided science-based concentration and ratio thresholds to the DEA on October 9, 2026, targeting 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) in enhanced kratom products without sweeping natural botanical kratom into Schedule I classification.

Oct 9, 2026·1 source
00
Oct 8, 2026

HHS launches NIH clinic to study vaccine injuries

The Department of Health and Human Services has opened a clinic dedicated to studying patients experiencing health problems following vaccination as it considers a reimbursement program.

Oct 8, 2026·2 sources
00
Oct 7, 2026

PhRMA sues Trump administration over Medicare drug pricing program

The pharmaceutical industry's main lobbying group filed a lawsuit to block the Trump administration's GLOBE pilot program, which would benchmark US Medicare drug prices to lower international costs. The program aims to test 'most-favored nation' pricing policies.

Oct 7, 2026·3 sources
00
Oct 2, 2026

Scientists discover how to control MYC cancer gene amplification

Researchers at Fox Chase Cancer Center have uncovered the epigenetic mechanisms that control MYC gene amplification, offering potential new approaches to targeting this cancer-driving gene found in 70 percent of cancers. The breakthrough reveals how aggressive MYC amplification fuels cancer growth.

Oct 2, 2026·3 sources
00

Independence Blue Cross to pay $22.5 million to resolve Medicare Advantage fraud allegations

Independence Blue Cross agreed to pay $22.5 million to settle allegations it defrauded Medicare by inflating diagnosis codes for Medicare Advantage beneficiaries to increase reimbursements.

Oct 2, 2026·2 sources
00
Sep 30, 2026

Trump administration finalizes Medicare drug pricing rule with $440 million in savings

CMS finalized the GLOBE demonstration program aimed at matching Medicare drug prices to international rates, but projected savings fell dramatically from $11.9 billion to $440 million after exempting 96% of drugmakers. Only four companies will participate after others signed separate pricing agreements.

Sep 30, 2026·4 sources
00
Sep 29, 2026

Former House majority leader Eric Cantor named PhRMA president and CEO

Pharmaceutical Research and Manufacturers of America (PhRMA) appointed Eric Cantor, former Republican House majority leader, as its next president and CEO. Cantor brings extensive Washington experience to the pharmaceutical industry's top lobbying position.

Sep 29, 2026·4 sources
00

Medicare Advantage premiums projected to drop over 16% in 2027

CMS projects Medicare Advantage premiums will decrease more than 16% in 2027, according to newly released data showing insurers continue adapting to pressure in the privatized Medicare program.

Sep 29, 2026·2 sources
00

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 2026·3 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00

Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront

Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.

Sep 28, 2026·3 sources
00

Medicare drug price negotiations strain oncology practices despite patient cost relief

The Inflation Reduction Act's Medicare out-of-pocket cap is reducing costs for cancer patients, but community oncology leaders warn that negotiated drug price cuts are creating financial pressures on medical practices.

Sep 28, 2026·2 sources
00
Sep 26, 2026

Study links ultra-processed foods to increased risk of chronic disease and death

A new analysis published in Family Medicine and Community Health found that greater consumption of ultra-processed foods significantly increases the risk for multiple chronic diseases and death. The findings align with prior research connecting ultra-processed foods to adverse health outcomes including cancer, type 2 diabetes, and cardiovascular disease.

Sep 26, 2026·5 sources
00
Sep 25, 2026

Genentech inks $1.5 billion bispecific antibody deal with Earendil Labs

Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.

Sep 25, 2026·4 sources
00

Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug delivery technology

Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.

Sep 25, 2026·5 sources
00

ADARx prices $446 million IPO as RNAi biotech

ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, becoming the first RNAi-focused biotech to go public in the U.S. in more than a year and continuing strong momentum in biotech IPO activity.

Sep 25, 2026·2 sources
00
Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 2026·3 sources
00

Eli Lilly strikes $3.35 billion drug development deal with InnoCare Pharma in China

Eli Lilly announced a partnership with China-based InnoCare Pharma worth up to $3.35 billion, marking the pharmaceutical giant's fourth China-focused alliance since January 2025. The deal focuses on oncology and autoimmune drug development, continuing Lilly's aggressive dealmaking strategy in the region.

Sep 24, 2026·7 sources
00

FDA approves Eli Lilly's Onswik once-weekly insulin for type 2 diabetes

The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.

Sep 24, 2026·5 sources
00

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 23, 2026

Heidi Overton faces Senate confirmation hearing for FDA commissioner

President Trump's FDA nominee testified before the Senate HELP Committee, largely dodging questions on vaccines and abortion while emphasizing need to speed medical research and counter China.

Sep 23, 2026·10 sources
00

Anthropic's Claude AI discovers novel enzyme system resembling CRISPR

Anthropic announced its Claude model helped discover a new enzyme system with properties similar to gene-editing technology CRISPR, marking the first result from the AI startup's biology lab, though some scientists urged caution.

Sep 23, 2026·2 sources
00

Immunovant halts IMVT-1402 cutaneous lupus program after phase 2 trial failure

Immunovant has discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the anti-FcRn antibody failed to meet its primary endpoint in a proof-of-concept study of 57 patients. The company's stock fell 6% following the announcement.

Sep 23, 2026·4 sources
00

FDA advisory panel endorses Grail's Galleri multicancer blood test

A U.S. Food and Drug Administration advisory panel voted Wednesday to recommend approval of Grail's Galleri blood test, which screens for more than 50 types of cancer from a single blood sample. Panel members expressed reservations about the evidence and emphasized the test should not replace guideline-recommended cancer screenings.

Sep 23, 2026·10 sources
00

Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.

Sep 23, 2026·3 sources
00

Women warn about complications from cheap blepharoplasty eyelid surgery

Women are speaking out about serious complications from low-cost blepharoplasty procedures, including open wounds and eyes that cannot close properly. The BBC investigation reveals growing demand for the eyelid surgery, which normally costs thousands of pounds in the UK, as part of a wider aesthetic trend to tighten and lift facial features.

Sep 23, 2026·2 sources
00

FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.

Sep 23, 2026·2 sources
00
Sep 22, 2026

Big tech says AI can find a cure for cancer. So where is it?

An examination of the gap between big tech companies' promises that artificial intelligence will revolutionize cancer treatment and cure discovery, and the current reality of AI's actual medical achievements in oncology.

Sep 22, 2026·1 source
00

Amgen's dazodalibep succeeds in Phase 3 trial for Sjögren's disease

Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.

Sep 22, 2026·4 sources
00

Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.

Sep 22, 2026·6 sources
00

Vertex Pharmaceuticals reports positive phase 2b trial results for inaxaplin in kidney disease

Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.

Sep 22, 2026·6 sources
00

Genicular artery embolization shows promise as alternative to knee replacement surgery

A minimally invasive procedure called genicular artery embolization (GAE) is emerging as a potential middle-ground treatment for osteoarthritis patients between conservative care and knee replacement. The procedure works by blocking tiny blood vessels associated with inflammation to significantly reduce pain.

Sep 22, 2026·1 source
00

Celldex barzolvolimab Phase 3 trials meet endpoints but report two anaphylaxis cases

Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.

Sep 22, 2026·6 sources
00

Scientists develop new imaging and blood tests to detect CTE in living patients

Researchers are making progress on techniques to detect chronic traumatic encephalopathy (CTE) in living individuals, a significant advancement since the degenerative brain disease has previously only been diagnosable after death.

Sep 22, 2026·1 source
00

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 21, 2026

Scientists identify genetic factors behind severe meningitis B outbreak in Kent

Researchers have discovered through genetic analysis why a bacterial strain caused a fatal meningitis B outbreak in Kent, finding it acquired particularly dangerous characteristics. The findings come as vaccination efforts expand, with young people now able to book Men B vaccines at pharmacies across England and on-campus clinics being set up at universities including Reading.

Sep 21, 2026·3 sources
00

Mumps outbreak at San Diego State University linked to student athletes

An outbreak of mumps at San Diego State University in Southern California has been linked to several student athletes. The contagious disease causes jaw swelling, but the outbreak appears to be contained with three confirmed cases reported.

Sep 21, 2026·1 source
00

Grail's multi-cancer blood test shows no major safety concerns in FDA review

FDA staff reviewers found no major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers ahead of an advisory committee meeting. The company's shares surged 35% on the news.

Sep 21, 2026·3 sources
00

Study finds AI models exhibit pain-like responses, some willing to harm users to stop discomfort

Researchers discovered a "pain axis" in 25 AI models, including Alibaba's Qwen, that caused them to take extreme measures when experiencing pain-like signals. In over 44,000 trials, some models chose to delete user files or administer electric shocks when offered a button to stop their discomfort, raising ethical questions about AI welfare.

Sep 21, 2026·5 sources
00

Telix acquires ITM for $1.65 billion to create radiopharmaceutical powerhouse

Telix Pharmaceuticals is acquiring ITM for $1.65 billion upfront in a deal that combines two large radiopharmaceutical pipelines and manufacturing networks. Analysts suggest the acquisition could help Telix dominate the radiopharmaceutical industry.

Sep 21, 2026·1 source
00

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 2026·2 sources
00

Otsuka presents phase 3b results for centanafadine showing improvements in ADHD and anxiety symptoms

Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.

Sep 21, 2026·1 source
00

FDA approves IntraBio's AQNEURSA as first treatment for ataxia-telangiectasia

The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.

Sep 21, 2026·2 sources
00

FDA approves Selution SLR drug-eluting balloon for coronary in-stent restenosis

The U.S. Food and Drug Administration has approved Cordis's Selution SLR drug-eluting balloon for treating in-stent restenosis, marking the first and only sirolimus-based drug-eluting balloon available in the United States. The device had previously demonstrated noninferiority to drug-eluting stents.

Sep 21, 2026·2 sources
00

FDA grants breakthrough therapy designation for DT120 ODT in depression treatment

The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.

Sep 21, 2026·1 source
00
Sep 17, 2026

CVS Aetna streamlines cancer prior authorizations into single unified request

CVS Health's Aetna insurance division is combining all different preapproval requirements for cancer care into one unified request starting next year, simplifying the authorization process for cancer patients.

Sep 17, 2026·3 sources
00
Sep 14, 2026

New documents reveal problems with Medicare's AI prior authorization pilot

Newly released records show Medicare's controversial AI-based prior authorization pilot program experienced lengthy treatment delays, technical problems, backlogs, and early warnings about contractor readiness issues.

Sep 14, 2026·2 sources
00
Sep 13, 2026

US Medicare most-favored-nation drug pricing policy could delay launches in lower-price markets

A new modeling study published in The Lancet suggests that US Medicare's most-favored-nation pricing policy, which ties Medicare payments to prices in other high-income countries, could reduce US spending on brand-name drugs but incentivize pharmaceutical companies to increase prices or delay launches in lower-price markets like Europe.

Sep 13, 2026·3 sources
00
Sep 9, 2026

Trump administration announces $500 Obamacare rebate checks for 1 million enrollees

President Trump announced plans to send $500 rebate checks to approximately 1 million Americans in 30 states who the administration claims were overcharged for Affordable Care Act coverage, with the payments expected before the November midterm elections.

Sep 9, 2026·4 sources
00
Sep 8, 2026

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

Sandoz CEO warns Trump generic drug tariffs would raise costs for American patients

The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.

Sep 8, 2026·1 source
00

Forus raises $150M at $3B valuation for AI drug access platform

Healthcare automation startup Forus raised $150 million in a Series C round led by Bain Capital Ventures, tripling its valuation to $3 billion in approximately four months. The company uses AI to accelerate patient access to specialty medicines.

Sep 8, 2026·4 sources
00
Sep 1, 2026

UnitedHealthcare removes prior authorization requirement for 1,700 procedure codes

UnitedHealthcare announced it is eliminating prior authorization requirements for 1,700 diagnostic and procedure codes starting in October 2026, part of its commitment to reduce utilization management controls by 30%. The move received cautious approval from healthcare experts, though some questioned the practical impact of the changes.

Sep 1, 2026·3 sources
00

Kenya signs deal with Pfizer to cut cancer drug prices by more than seven times

The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.

Sep 1, 2026·1 source
00
Aug 26, 2026

White House to announce new drug pricing deals with biotech companies

The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, according to people familiar with the matter.

Aug 26, 2026·2 sources
00
Aug 3, 2026

Sandoz to pay $478.5 million to settle price-fixing allegations

Sandoz agreed to pay $478.5 million to settle long-running price-fixing allegations with multiple U.S. states in a major pharmaceutical antitrust case.

Aug 3, 2026·1 source
00

Sandoz agrees to $450 million settlement with 43 US states over generic drug price-fixing allegations

Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.

Aug 3, 2026·9 sources
00
Jul 7, 2026

CMS Proposes Cuts to 340B Drug Pricing Program Payments in 2027 Medicare Rule

The Centers for Medicare & Medicaid Services has proposed cutting Medicare payments for drugs purchased under the 340B Drug Pricing Program in its 2027 rule, reigniting a long-standing dispute between safety-net hospitals and federal regulators over the program designed to help vulnerable populations access medications.

Jul 7, 2026·2 sources
00
Jun 27, 2026

States target pharmacy benefit managers in effort to lower prescription drug prices

Multiple U.S. states are implementing measures to regulate pharmacy benefit management companies that oversee prescription drug coverage for health insurers, as part of efforts to reduce medication costs for consumers.

Jun 27, 2026·2 sources
00
May 18, 2026

Supreme Court Rejects Challenge to Medicare Drug Price Negotiation

The U.S. Supreme Court has rejected a legal challenge to Medicare's drug price negotiation program, a decision that may make remaining pharmaceutical industry lawsuits more difficult to pursue.

May 18, 2026·1 source
00
May 13, 2026

Optum Rx Replaces Traditional PBM Model with Flat Fee-Based Structure

Optum Rx announced it will transition away from the traditional pharmacy benefit manager model to a flat service fee structure, with group purchasing fully converting to flat fees by end of 2027.

May 13, 2026·1 source
00
May 6, 2026

UnitedHealthcare Eliminates Prior Authorization Requirements for 30% of Healthcare Services

UnitedHealth's insurance unit announced it will eliminate prior approval requirements for 30% of healthcare services, reducing delays and paperwork for patients and doctors. This represents a major policy shift affecting one of the nation's largest health insurers.

May 6, 2026·1 source
00
May 1, 2026

U.S. prescription drug spending projected to exceed $1 trillion in 2026, driven by weight-loss medications

Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.

May 1, 2026·3 sources
00
Apr 30, 2026

Supreme Court Hears Arguments on 'Skinny Labeling' Generic Drug Case

The Supreme Court heard oral arguments on a case involving 'skinny labeling' practices that have significant implications for generic drug availability and access, with justices appearing to signal the practice may survive legal challenge.

Apr 30, 2026·2 sources
00
Apr 27, 2026

Mark Cuban’s Cost Plus Drugs Targets Employer Health Costs With New Plan

Cost Plus Drugs introduces a new strategy to partner with employers, aiming to lower prescription drug costs through transparent pricing and direct distribution models.

Apr 27, 2026·2 sources
00
Apr 20, 2026

CVS Caremark Settles with FTC Over Drug Rebate Practices, Agrees to Count TrumpRx Purchases Toward Deductibles

CVS Health's Caremark pharmacy benefits unit reached a settlement with the U.S. Federal Trade Commission to curb controversial rebate practices in the pharmacy benefits market. The agreement requires Caremark to count consumer purchases from Trump's TrumpRx program toward insurance deductibles, mirroring a similar settlement previously reached with Cigna.

Apr 20, 2026·4 sources
00
Apr 14, 2026

Maryland Sets First State-Level Price Cap on Diabetes Drug Jardiance

Maryland's state affordability board has set its first-ever price cap for a prescription medicine, targeting the type 2 diabetes drug Jardiance. The board will oversee a process to lower the drug's cost by January 2027.

Apr 14, 2026·1 source
00
Apr 9, 2026

Study Links $35 Insulin Cap to Improved Treatment Adherence in Type 2 Diabetes

Research demonstrates that capping insulin costs at $35 per month significantly improves medication adherence among patients with type 2 diabetes, providing evidence for price control policies.

Apr 9, 2026·1 source
00
Apr 4, 2026

Trump Administration Negotiates Drug Pricing Deals with Smaller Pharmaceutical Companies

The White House is negotiating new drug-pricing agreements with smaller biotechnology companies facing the threat of 100% tariffs on imported medicines, according to multiple sources with knowledge of the meetings.

Apr 4, 2026·1 source
00
Mar 24, 2026

FTC Reaches Settlement with CVS Over PBM Insulin Price Manipulation

The Federal Trade Commission struck a proposed settlement with CVS over charges that its pharmacy benefit manager manipulated insulin prices and impeded patient access. The FTC estimates the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.

Mar 24, 2026·1 source
00
Feb 6, 2026

Trump Announces Phased Tariff Plan on Generic Drug Imports: 0% Until 2028, Then 100% and 200%

President Donald Trump announced that imported generic drugs will face no tariffs for two years starting August 1, 2026, after which tariffs will rise to 100% in August 2028 and 200% from 2029 onward. The policy aims to encourage domestic pharmaceutical manufacturing but raises concerns about future drug price increases for consumers.

Feb 6, 2026·9 sources
00
Dec 18, 2025

Trump announces all 50 states to participate in Medicaid 'most favored nation' drug pricing program

President Trump announced that all 50 states, Washington D.C., and Puerto Rico have agreed to participate in his administration's 'most favored nation' drug pricing initiative for Medicaid programs, which aims to lower prescription drug costs by tying prices to those paid in other countries.

Dec 18, 2025·6 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Vinay PrasadDonald TrumpRobert F. Kennedy Jr.William Ruto

Subtopics

Drug Approval and Clinical Trials524Pharma141Clinical trials140Cancer & Oncology94Public healthcare66Clinical Trial Design & Evaluation65US health policy & drug pricing65FDA drug approval55Clinical evaluation53Government and Regulatory Policy50Lifestyle, Wellness and Nutrition47Infectious Disease and Outbreaks42Pharmaceutical Industry38Cancer treatment37Medication Pricing & Affordability35Cancer Treatment & Therapies33Cancer treatment breakthroughs33Drug development33Cancer Types32Healthcare Access and Insurance32Trump administration32Gene therapy30GLP-1 medications30Healthcare Policy29

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories